BAYER AG NA O.N.
Commented by Armin Schulz on February 24th, 2026 | 07:15 CET
MustGrow Biologics and its partnership with Bayer: Why the stock is only just getting started
Global agriculture is facing a paradox. It needs to feed more people, but with fewer chemical inputs. Worldwide, 460 pesticides are now banned or restricted across 162 countries. The era of synthetic active ingredients is coming to an end – but what comes next? A Canadian company believes it has found the answer. It grows in the field, is spicy and yellow: mustard. MustGrow Biologics has developed a technology that uses the natural defenses of the mustard plant to remediate soils and increase yields. What sounds like a niche idea could turn out to be one of the most exciting investments in the agricultural sector.
Read
Commented by Nico Popp on February 20th, 2026 | 07:25 CET
Agricultural revolution breaks the billion-dollar barrier: Why MustGrow Biologics, Bayer, and Bioceres Crop Solutions are ending the era of chemicals
The agricultural industry is currently transitioning from toxic chemicals to high-performance biologics. In this market environment, various players are positioning themselves with complementary strategies to capture the gigantic market for sustainable crop protection, which is expected to generate billions of dollars in revenue in the future. The ongoing deterioration of farmland and increasingly restrictive regulations are forcing farmers and corporations alike to rethink their approaches. It is no longer just about purely ecological ideals, but about food for humanity. Established agricultural giants and innovative technology companies are working feverishly to secure yields without further depleting nature. In this race, clear winners are emerging who are laying the foundation for the agriculture of the future and offering investors unprecedented opportunities. MustGrow Biologics is an exciting candidate.
Read
Commented by Armin Schulz on February 17th, 2026 | 08:10 CET
Cancer Research as a Growth Driver: How Bayer, Vidac Pharma, and Pfizer can enrich your portfolio
Oncology will be put to the test for the pharmaceutical industry in 2026. Never before have so many highly specialized active ingredients been on the verge of market launch at the same time. While checkpoint inhibitors and targeted therapies are revolutionizing treatment, business models are shifting from broad-based approaches to precision medicine. But the reality remains complex: between medical advances, narrow patient groups, and pressure on prices, companies need to readjust. Current developments at Bayer, Vidac Pharma, and Pfizer show how three players with different strategies are responding to this change.
Read
Commented by Fabian Lorenz on February 10th, 2026 | 07:00 CET
Rheinmetall, Bayer, Avrupa Minerals: Stocks for Europe's independence in defense, pharmaceuticals, and raw materials!
Europe is working feverishly to achieve independence. This applies, among other things, to defense, raw materials, and medicines. Investors can profit from these three stocks. Avrupa Minerals is developing raw material projects in Finland, Portugal, and other countries, skillfully diversifying to reduce risks. The stock is still largely unknown, but this is likely to change soon. Rheinmetall is a basic investment, although there was a noticeable drop in its share price last week. Are expectations too high? At the beginning of 2025, there were hardly any expectations for Bayer. This made the comeback of the company and its stock all the more spectacular. Recently, positive study results have once again caused excitement. The next blockbuster is in the pipeline.
Read
Commented by Fabian Lorenz on February 9th, 2026 | 07:30 CET
Bayer shares in the fast lane! Partner MustGrow Biologics facing revaluation!
For Bayer, things are currently going extremely well. The group is bringing its problem areas under control while reporting tangible progress in its pharmaceutical business. In the shadow of this, the company has secured the license for a new biologically safe product platform for fertilizers. Its partner in this venture is MustGrow Biologics. The company is on the verge of transitioning from research to commercialization, with management planning a market launch later this year. Production capacities are already being expanded in Asia. Against this backdrop, MustGrow shares appear poised for a revaluation - and the company is increasingly emerging as a potential takeover candidate.
Read
Commented by Armin Schulz on February 5th, 2026 | 09:30 CET
SAP in free fall! RE Royalties soaring - and how is Bayer's turnaround progressing?
The stock market is divided. Established names are tumbling, while niche players are booming. Software giant SAP is facing a crisis of confidence after disappointing forecasts. Its share price slump highlights how unforgiving markets are toward stagnating growth. At the same time, a smaller name is attracting attention. RE Royalties is benefiting from the exploding demand for electricity from AI with its renewable energy business model and is attracting investors with generous dividends. In between, pharmaceutical giant Bayer is battling the legacy issues of a prolonged downturn and showing that its turnaround is increasingly gaining traction. We take a closer look at the current situation.
Read
Commented by André Will-Laudien on February 4th, 2026 | 07:10 CET
Starting signal! Biotech sector benefits from rotation! Keep an eye on Evotec, Bayer, Vidac Pharma, and BioNTech
The stock market has started 2026 on a positive note. The mining and commodities sector recently proved that return opportunities are not limited to the technology sector, with several stocks doubling in price and a few even increasing tenfold. A breath of fresh air is needed, because other sectors also want to enjoy the stock market spring. Life science stocks have indeed taken a break for almost three years. But now they are back! After a long period of silence, selected companies are showing the first signs of a technical recovery. For investors with a penchant for opportunities and timing, now is the time to rethink old strategies and realign portfolios. In cancer research, recent breakthroughs in personalized immunotherapies have significantly increased the prospects of success for clinical trials. We take a closer look.
Read
Commented by Nico Popp on February 4th, 2026 | 07:05 CET
Solution to a billion-dollar problem: MustGrow Biologics validates business model – Revolutionary news also for Bayer and Corteva Agriscience
Canola is to Canada what oil is to Saudi Arabia: an economic driver of enormous proportions. With an estimated production value of around CAD 14 billion in 2025, the yellow-flowering crop is the "green gold" of the prairie. Yet this billion-dollar market is in danger: clubroot, an aggressive soil-borne disease, threatens crops and is already causing annual losses exceeding CAD 500 million. Previous solutions have reached their biological limits, but now the Canadian AgriTech company MustGrow Biologics is reporting a decisive success. As the company announced on Tuesday, its proprietary TerraMG™ technology has not only suppressed the disease in large-scale field trials, but also significantly increased yields. For agricultural giants like Bayer and Corteva, this could be the decisive lever to protect their high-performance seed varieties over the long term.
Read
Commented by André Will-Laudien on January 26th, 2026 | 07:30 CET
Biotech and life sciences are booming, and now Mercosur is joining the fray! Bayer, MustGrow, Novo Nordisk, and BioNxt Solutions in focus
The 2026 stock market year has a few surprises in store for investors. In addition to a quick resolution to the Greenland dispute, the Mercosur trade agreement with several South American countries is also moving forward. This agreement is particularly significant for the agricultural industry. This global sector of human supply is increasingly characterized by regulatory pressure, which is effectively ending the use of many synthetic pesticides and fertilizers. This development is forcing established agricultural companies to integrate effective biological alternatives into their portfolios faster than planned. In this environment, MustGrow Biologics is positioning itself as a strategic technology provider whose active ingredients have already been validated by leading market players. An expanded sector view also covers the life sciences industry with the protagonists Bayer, Novo Nordisk, and BioNxt. Up 50% in just a few weeks, here they are!
Read
Commented by Nico Popp on January 23rd, 2026 | 07:15 CET
Revolution in agricultural chemistry: How MustGrow Biologics is benefiting from the plight of Bayer and Corteva
Global agriculture is at a historic turning point, driven less by a belief in technological progress than by regulatory necessity. For decades, global food security has been based on synthetic pesticides and fertilizers, but that era is rapidly coming to an end. Authorities from Brussels to California are tightening the screws and banning established active ingredients one after the other because their ecological collateral damage is no longer tolerated. For the agricultural giants, this poses an existential threat: their full warehouses are in danger of becoming worthless if they do not find effective biological alternatives quickly enough. In the current extremely hectic environment in industry, which is characterized by billion-dollar acquisitions and strategic alliances, new power structures are emerging. While Corteva Agriscience is aggressively buying market share with its chequebook and Bayer is pushing ahead with its portfolio restructuring, the Canadian company MustGrow Biologics has carved out a position that is considered the "sweet spot" in the industry. The Company is the technology partner whose active ingredients have already been validated and licensed by the market leaders.
Read